, Volume 52, Issue 6, pp 799–804 | Cite as

Prospects for the Development of a Vaccine Against Helicobacter pylori

Current Opinion


Over 50% of the world population is chronically infected by the gastric pathogen, Helicobacter pylori, which is responsible for most peptic ulcer disease and is closely associated with adenocarcinoma of the stomach. Current therapies for peptic ulcer disease include antibiotic eradication of H. pylori infection. While effective, the high cost, difficulty of patient compliance with the treatment regimens, and risks of selection for resistant strains make these therapies impractical on a large scale. Studies of the pathogenesis of H. pylori have led to the identification of bacterial antigens as candidates for inclusion in novel vaccines against this disease. Both prophylactic and therapeutic vaccination have been demonstrated in animal models of Helicobacter infection. Preclinical evaluations of several antigens are at present under way and trials of vaccination in humans are planned.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Blaser MJ. The bacteria behind ulcers. Sci Am 1996; 274: 104–7CrossRefPubMedGoogle Scholar
  2. 2.
    Morris AJ, Ali MR, Nicholson GI, et al. Long-term follow-up of voluntary ingestion of Helicobacter pylori. Ann Intern Med 1991; 114: 662–3CrossRefPubMedGoogle Scholar
  3. 3.
    Sobala GM, Crabtree JE, Dixon MF, et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991; 32: 1415–8CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Marshall BJ. The Campylobacter pylori story. Scand J Gastroenterol Suppl. 1988; 146: 58–66CrossRefPubMedGoogle Scholar
  5. 5.
    Tytgat GNJ. Treatments that impact favourably upon the eradication of Helicobacter pylori and ulcer recurrence. Aliment Pharmacol Ther 1994; 8: 359–68CrossRefPubMedGoogle Scholar
  6. 6.
    Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med 1991; 325: 1127–31CrossRefPubMedGoogle Scholar
  7. 7.
    Parsonnet J, Hansen S, Rodriguez L, et al. Helicobacter pylori infection and gastric lymphoma. N Engl J Med 1994; 330: 1267–71CrossRefPubMedGoogle Scholar
  8. 8.
    Mobley HL, Cortesia MJ, Rosenthal LE, et al. Characterization of urease from Campylobacter pylori. J Clin Microbiol 1988; 26: 831–6PubMedPubMedCentralGoogle Scholar
  9. 9.
    Labigne A, Cussac V, Courcoux P. Shuttle cloning and nucleotide sequences of Helicobacter pylori genes responsible for urease activity. J Bacteriol 1991; 173: 1920–31CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    Josenhans C, Labigne A, Suerbaum S. Comparative ultrastructural and functional studies of Helicobacter pylori and Helicobacter mustelae flagellin mutants: both flagellin subunits, FlaA and FlaB, are necessary for full motility in Helicobacter species. J Bacteriol 1995; 177: 3010–20CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Evans DG, Karjalainen TK, Evans Jr DJ, et al. Cloning, nucleotide sequence, and expression of a gene encoding an adhesin subunit protein of Helicobacter pylori. J Bacteriol 1993; 175: 674–83CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    O’Toole PW, Janzon L, Doig P, et al. The putative neuraminyllactose-binding hemagglutinin HpaA of Helicobacter pylori CCUG 17874 is a lipoprotein. J Bacteriol 1995; 177: 6049–57CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Leunk RD, Johnson PT, David BC, et al. Cytotoxic activity in broth-culture filtrates of Campylobacter pylori. J Med Microbiol 1988; 26: 93–9CrossRefPubMedGoogle Scholar
  14. 14.
    Telford JL, Ghiara P, Dell’Orco M, et al. Gene structure of the Helicobacter pylori cytotoxin and evidence of its key role in gastric disease. J Exp Med 1994; 179: 1653–8CrossRefPubMedGoogle Scholar
  15. 15.
    Xiang ZY, Censini S, Bayeli PF, et al. Analysis of expression of CagA and VacA virulence factors in 43 strains of Helicobacter pylori reveals that clinical isolates can be divided into two major types and that CagA is not necessary for expression of the vacuolating cytotoxin. Infect Immun 1995; 63: 94–8PubMedPubMedCentralGoogle Scholar
  16. 16.
    Covacci A, Censini S, Bugnoli M, et al. Molecular characterization of the 128-kDa immunodominant antigen of Helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci USA 1993; 90: 5791–5CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Xiang Z, Bugnoli M, Ponzetto A, et al. Detection in an enzyme immunoassay of an immune response to a recombinant fragment of the 128 kilodalton protein (CagA) of Helicobacter pylori. Eur J Clin Microbiol Infect Dis 1993; 12: 739–45CrossRefPubMedGoogle Scholar
  18. 18.
    Blaser MJ, Perez-Perez GI, Kleanthous H, et al. Infection with Helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res 1995; 55: 2111–5PubMedGoogle Scholar
  19. 19.
    Telford JL, Covacci A, Ghiara P, et al. Unravelling the pathogenic role of Helicobacter pylori in peptic ulcer: potential for new therapies and vaccines. Trends Biotechnol 1994; 12: 420–6CrossRefPubMedGoogle Scholar
  20. 20.
    Atherton JC, Cao P, Peek RM, et al. Mosaicism in vacuolating cytotoxin alleles of Helicobacter pylori — association of specific vacA types with cytotoxin production and peptic ulceration. J Biol Chem 1995; 270: 17771–7CrossRefPubMedGoogle Scholar
  21. 21.
    Ghiara P, Marchetti M, Blaser MJ, et al. Role of the Helicobacter pylori virulence factors vacuolating cytotoxin, CagA, and urease in a mouse model of disease. Infect Immun 1995; 63: 4154–60PubMedPubMedCentralGoogle Scholar
  22. 22.
    Marchetti M, Arico B, Burroni D, et al. Development of a mouse model of Helicobacter pylori infection that mimics human disease. Science 1995; 267: 1655–8CrossRefPubMedGoogle Scholar
  23. 23.
    Crabtree JE, Xiang Z, Lindley IJD, et al. Induction of interleukin-8 secretion from gastric epithelial cells by a CagA negative isogenic mutant of Helicobacter pylori. J Clin Pathol 1995; 48: 967–9CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen M, Lee A, Hazell S. Immunisation against gastric helicobacter infection in a mouse/Helicobacter felis model [letter]. Lancet 1992; 339: 1120–1CrossRefPubMedGoogle Scholar
  25. 25.
    Walker RI. New strategies for using mucosal vaccination to achieve more effective immunization. Vaccine 1994; 12: 387–400CrossRefPubMedGoogle Scholar
  26. 26.
    Corthesy-Theulaz I, Haas R, Davin C, et al. Helicobacter pylori urease protection against Helicobacter felis infection in mice. Acta Gastroenterol Belgica 1993; 56: 64Google Scholar
  27. 27.
    Ferrero RL, Thiberge JM, Huerre M, et al. Recombinant antigens prepared from the urease subunits of Helicobacter spp: evidence of protection in a mouse model of gastric infection. Infect Immun 1994; 62: 4981–9PubMedPubMedCentralGoogle Scholar
  28. 28.
    Michetti P, Corthesy-Theulaz I, Davin C, et al. Immunization of BALB/c mice against Helicobacter felis infection with H. pylori urease. Gastroenterology 1994; 107: 1002–11CrossRefPubMedGoogle Scholar
  29. 29.
    Ghiara P, Marchetti M, Di Tommaso A, et al. Infection by Helicobacter pylori in a mouse model that mimics human disease: protection by oral immunization [abstract]. Gut 1995; 37 Suppl. 1:A51Google Scholar
  30. 30.
    Ferrero RL, Thiberge JM, Kansau I, et al. The GroES homolog of Helicobacter pylori confers protective immunity against mucosal infection in mice. Proc Natl Acad Sci USA. 1995; 92: 6499–503CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Corthésy-Theulaz I, Vaney AC, Haas R, et al. H. pylori urease B subunit as a therapeutical vaccine against H. felis infection [abstract]. Gastroenterology 1994; 106 (4 Pt 2): A668Google Scholar
  32. 32.
    Doidge C, Gust I, Lee A, et al. Therapeutic immunisation against Helicobacter infection. Lancet 1994; 343: 914–5CrossRefPubMedGoogle Scholar
  33. 33.
    Lee CK, Weltzin R, Thomas WD, et al. Oral immunization with recombinant Helicobacter pylori urease induces secretory IgA antibodies and protects mice from challenge with Helicobacter felis. J Infect Dis 1995; 172: 161–72CrossRefPubMedGoogle Scholar
  34. 34.
    Lee A, Chen MH. Successful immunization against gastric infection with Helicobacter species: use of a cholera toxin B-subunit-whole-cell vaccine. Infect Immun 1994; 62: 3594–7PubMedPubMedCentralGoogle Scholar
  35. 35.
    Nedrud J, Blanchard T, Czinn S, et al. Recombinant cholera toxin B subunit is not an adjuvant for oral immunization against Helicobacter felis in mice [abstract]. J Cell Biochem 1995; Suppl. 19A: 261Google Scholar
  36. 36.
    Douce G, Trucotte C, Cropley I, et al. Mutants of Escherichia coli heat-labile toxin lacking ADP-ribosyltrasferase activity act as nontoxic, mucosal adjuvants. Proc Natl Acad Sci USA 1995; 92: 1644–8CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Adis International Limited 1996

Authors and Affiliations

  1. 1.IRISChiron-Biocine SpA Institute for Immunobiological ResearchSienaItaly

Personalised recommendations